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Abstract
Introduction: We have previously shown that the concentrations of D-dimer are significantly elevated in saliva compared with plasma. Saliva of-
fers several advantages compared with blood analysis. We hypothesised that human saliva contains plasminogen activator inhibitor-1 (PAI-1) and 
that the concentrations are not affected by the time of saliva collection. The aim was to adopt and validate an immunoassay to quantify PAI-1 con-
centrations in saliva and to determine whether saliva collection time has an influence in the measurement.
Materials and methods: Two saliva samples (morning and afternoon) from the same day were collected from healthy subjects (N = 40) who have 
had no underlying heart conditions. A customized AlphaLISA® immunoassay (PerkinElmer®, MA, USA) was adopted and used to quantify PAI-1 con-
centrations. We validated the analytical performance of the customized immunoassay by calculating recovery of known amount of analyte spiked 
in saliva.
Results: The recovery (95.03%), intra- (8.59%) and inter-assay (7.52%) variations were within the acceptable ranges. The median salivary PAI-1 
concentrations were 394 pg/mL (interquartile ranges (IQR) 243.4-833.1 pg/mL) in the morning and 376 (129.1-615.4) pg/mL in the afternoon and the 
plasma concentration was 59,000 (24,000-110,000) pg/mL. Salivary PAI-1 did not correlate with plasma (P = 0.812).
Conclusions: The adopted immunoassay produced acceptable assay sensitivity and specificity. The data demonstrated that saliva contains PAI-1 
and that its concentration is not affected by the time of saliva collection. There is no correlation between salivary and plasma PAI-1 concentrations. 
Further studies are required to demonstrate the utility of salivary PAI-1 in CVD risk factor studies.
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Cardiovascular disease (CVDs) is the number one 
killer world-wide, and about 50% of all deaths are 
associated with high blood pressure (1). Over the 
years, a series of high risk factors have been estab-
lished for CVDs including hypertension, dyslipi-
demia, diabetes mellitus, age, unhealthy diet, 
physical inactivity, tobacco use and excessive use 
of alcohol (1). However, it is hard to fully under-
stand the cardiovascular risk with only these risk 
factors (2,3). Newer biomarkers, including plas-
minogen activator inhibitor 1 (PAI-1) (4), brain type 
natriuretic peptide (BNP) (5), N-terminal prohor-
mone of BNP (NT-proBNP) (6,7), C-reactive protein 
(CRP) (8), D-dimer (9,10), troponin I (11) and inflam-
matory mediators (12) have been associated with 
CVD risk. Patient stratification can be enhanced by 
measuring these biomarkers simultaneously (13).
Previously, we have quantified D-dimer concentra-
tions in human saliva and demonstrated a two-
fold increase in saliva compared with plasma col-
lected from the same individuals (9). These find-
ings prompted us to further investigate other pro-
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teins involved in the coagulation cascade. Thus, 
we investigated the PAI-1 concentrations in saliva. 
During coagulation, prothrombinase cleaves pro-
thrombin into thrombin which transforms fibrino-
gen into highly self-adhesive fibrin monomers (14). 
The inhibition of fibrinolysis is performed by two 
types of PAIs: PAI-1 and PAI-2. A previous study has 
shown that there is tissue type plasminogen acti-
vator and PAI-1 activity in human parotid saliva 
(15). A more recent study using a commercial en-
zyme-linked immunosorbent assay (ELISA) kit de-
tected the presence of only PAI-2, yet both PAI-1 and 
PAI-2 are expressed in salivary gland tissues (16).
Fibrinolytic deficiency is linked to a higher risk of 
developing CVDs including myocardial infarction 
(17) and coronary artery disease (18). Previous stud-
ies have demonstrated that high plasma PAI-1 con-
centrations are linked to myocardial infarction (17), 
stroke (19) and coronary artery disease (20). Thus, 
PAI-1 is considered as a useful biomarker for pre-
dicting the risk of coronary events (13).
Salivary secretions contain most of the biomole-
cules that are present in blood or urine (21-23). Sa-
liva samples can be easily collected without the 
need for medical staff or hypodermic needles and 
saliva does not clot compared with blood, making 
the former biological fluid ideal for large popula-
tion based screening studies. Additionally, saliva 
sample collection is very robust and saliva sample 
collection has significantly lower physiological and 
psychological impact on the donor than blood col-
lections (8,24,25). Furthermore saliva can be col-
lected and stored in stabilising solution several 
days later prior to being received by a testing cen-
tre. Saliva has even been used as a biological fluid 
for the diagnosis of ischemic heart disease (8), 
heart failure (6), in oral cancers (23). However, the 
concentration of the analytes in saliva are often 
much lower than in blood, and warrants higher 
sensitivity detection technologies. We hypothesise 
that human saliva contains PAI-1 and that the con-
centrations are not affected by the time of saliva 
collection (i.e. morning saliva sample vs. afternoon 
saliva). The aims were to adopt and validate an im-
munoassay to quantify PAI-1 concentrations in sa-
liva and to determine whether saliva collection 
time has an influence in the measurement.
Materials and methods
Subjects
The University of Queensland Medical Ethical Insti-
tutional Board approved the protocol of this study 
and subjects provided written informed consent. 
We recruited 40 healthy subjects (20 males (19-36 
years) and 20 females (19-25 years)) from the Uni-
versity of Queensland students and staff between 
August 22, 2012 and December 6, 2012. The sub-
jects were of Asian and European descent, had 
good oral hygiene and showed no evidences of fe-
ver and/or respiratory tract infection. All subjects 
underwent a sample questionnaire which provid-
ed us with their medical history. In this study, we 
excluded subjects who have had any comorbid 
oral disease (e.g. periodontal disease and gingivi-
tis), active infection, autoimmune disease, malig-
nancy or who are smokers, undergoing dental 
treatment or any kind of medical treatment, den-
ture wearers, pregnant and or had a recent opera-
tion or trauma. Written informed consents were 
obtained from all subjects before sample collec-
tion and none of the subjects were on any type of 
medication.
Samples
Saliva and blood samples from each subject were 
collected on the same day. Blood samples were 
collected into 4 mL sodium citrate tubes (Greiner 
VACUETTE® # 454327, Greiner Bio-one, Graz, Aus-
tria) by an experienced phlebotomist (Queensland 
Medical Laboratory Pathology Services, University 
of Queensland Blood Collection Centre). The blood 
samples were collected between 09.00 and 16.00 
hours immediately after either the morning or af-
ternoon saliva collection. Due to the impracticality 
of collecting multiple blood samples from the 
same subject, only one blood sample was collect-
ed from each subject. In order to obtain plasma, 
the blood samples were centrifuged at 1500 x g at 
room temperature for 15 minutes immediately af-
ter collection. The plasma samples were then aliq-
uoted, de-identified and stored at -80 °C until anal-
ysis. Saliva samples were collected into sterile Fal-
con Polypropylene Conical Tubes (50 mL, BD Bio-
science, #352070, San Jose, CA, USA). The saliva 
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was collected by an unstimulated resting drool 
method which is well described in literature (26,27). 
In order to obtain a relatively constant baseline, 
we asked all subjects to stop eating and drinking 
(with the exception of water), one to two hours 
prior to saliva donation. We collected one saliva 
sample from each subject in the morning (08.00-
12.00 hours) and one saliva sample in the after-
noon (14.00-16.00 hours) to investigate the diurnal 
variation of PAI-1 concentrations. Similar to the sa-
liva samples, all the plasma samples were aliquot-
ed and de-identified immediately post collection. 
The saliva was then diluted 90% with 1X 
AlphaLISA(R) immunoassay buffer (Product-No: 
AL286 C/F, Perkin Elmer®, MA, USA) and stored at 
-80 °C until analysis.
The adoptation and the validation of PAI-1 Al-
phaLISA® Immunoassay
In this study we utilised a highly sensitive AlphaLI-
SA® technology (PerkinElmer®, Boston, MA, USA). It 
is a homogeneous, bead-based sandwiched im-
munoassay that offers many advantages over tra-
ditional ELISA including relatively higher sensitivi-
ty, low sample volumes can be accurately analysed 
in a less labour consuming manner. The PAI-1 Al-
phaLISA® kit is validated for the use with human 
serum/ plasma samples and cell culture superna-
tants. This kit has not been validated to measure 
PAI-1 in saliva samples. In the first instance we per-
formed a pilot study to determine likely PAI-1 con-
centration range. This was done to make sure that 
the background PAI-1 concentrations are low and 
that one is able to obtain a relatively higher signal 
to noise ratio. Saliva samples collected form 
healthy subjects were diluted using immunoassay 
buffer. Once the saliva concentration range was 
established, standards were prepared by diluting 
PAI-1 standard from the PAI-1 AlphaLISA® kit (Prod-
uct-No: AL286 C/F, Perkin Elmer®, MA, USA) in a 
90% saliva matrix, by using pooled saliva (9 mL) 
and 1 mL of immunoassay buffer from the kit. The 
matrix was prepared by pooling saliva from 10 
healthy subjects. A standard curve was generated 
using twelve standards at the concentration of 
1,000,000, 300,000, 100,000, 30,000, 10,000, 3,000, 
1,000, 300, 100, 30, 10 and 3 pg/mL. Quality con-
trols were also prepared in a similar manner by di-
luting a known concentration of PAI-1 in 90% sali-
va. The quality controls were analysed in the assay 
runs to provide recoveries. For the plasma meas-
urement, the same strategy was used except that 
the standards were prepared in pooled plasma (N 
= 3, 0.1% of pooled plasma).
To measure the concentration of PAI-1 in plasma 
and saliva samples, in house adopted PAI-1 Al-
phaLISA® kit (Product-No: AL286 C/F, Perkin Elmer®, 
MA, USA) was used. It contains a biotinylated anti-
PAI-1 polyclonal antibody, which binds to the 
streptavidin-coated donor beads while the anti-
PAI-1 polyclonal antibody is conjugated to the ac-
ceptor beads. In the presence of PAI-1, the beads 
come into close proximity. After excitation at 680 
nm, donor beads will give out singlet oxygen mol-
ecules that trigger a cascade of energy transfer in 
the acceptor beads, resulting in a sharp peak of 
light emission at 615 nm.
The samples were analyzed (triplicate) in 384 well 
ProxiPlatesTM (Perkin Elmer®, MA, USA). We de-
creased the total reaction volumes from 50 µL to 
10 µL and changed the final concentration of 
streptavidin donor beads from 40 µg/mL to 12.5 
µg/mL. Briefly, the immunoassay consisted of add-
ing 1 µL of sample/analyte into a 384-well micro-
plate, and then adding 2 µL of biotinylated anti-
body (10 nM) followed by a 30 minutes incubation 
at room temperature. After the first incubation, 2 
µL of acceptor bead (100 µg/mL) was added, fol-
lowed by 60 minutes incubation at room tempera-
ture. Since the streptavidin donor beads are light 
sensitive, 5 µL streptavidin donor beads (50 µg/
mL) was added to each well under subdued labo-
ratory lighting. The microplate was read using an 
EnSpire™ plate reader (Perkin Elmer®, MA, USA) af-
ter 30 minutes of incubation in the dark at room 
temperature.
Assay performance characteristics for the in 
house developed salivary PAI-1 AlphaLISA(R)
Recovery
Three known concentrations of commercial re-
combinant PAI-1 (Product-No: 1728540, Perkin 
Elmer®, MA, USA) were spiked in pooled saliva col-
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lected from healthy subjects (N = 4) in order to de-
termine analyte recovery. Both spiked and un-
spiked pooled saliva were measured in the same 
AlphaLISA(R) immunoassay. The percentage recov-
ery of the three spiked saliva samples was calcu-
lated in reference to respective un-spiked pooled 
saliva samples in a single AlphaLISA(R) immu-
noassay, using the following equation (28):
Percentage recovery (%) = (PAI-1 concentration 
in spiked saliva — PAI-1 concentration in un-spi-
ked saliva) / (amount of spiked PAI-1) × 100%
Intra-and inter-assay coefficient of variation for the 
PAI-1 AlphaLISA(R) assay
To determine intra- and inter- assay variations, trip-
licates of saliva samples from 40 healthy subjects 
were analysed in one AlphaLISA(R) PAI-1 immu-
noassay run and then three independent 
AlphaLISA(R) PAI-1 immunoassays runs, respective-
ly (28). Intra- and inter-assay variations were ex-
pressed by intra- or inter- assay coefficient of varia-
tion (%CV). %CV was calculated using the follow-
ing equation:
%CV= (Mean of SD) / (Mean) × 100%
Limit of detection and limit of quantification for 
PAI-1 AlphaLISA (R) immunoassay
To determine the assay’s limit of detection (LOD) 
and limit of quantification (LOQ), 9 blanks (2.5% 
pooled saliva diluted in 1X AlphaLISA Immu-
noassay buffer) were measured in one immu-
noassay run. The LOD and LOQ for the salivary 
PAI-1 immunoassay was read from a sigmoidal-
dose response curve based on LOD and LOQ sig-
nal counts derived from the equations (29):
LOD signal count = (Average of black signal 
count) + 3 × (standard deviation of blank signal)
LOQ signal count = (Average of black signal 
count) + 10 × (standard deviation of blank signal)
Statistical analysis
All statistical analyses were performed using 
GraphPad Prism 5 software version 6.02 (GraphPad 
Software Inc., La Jolla, CA, USA). We generated a 
standard curve by plotting the “raw” AlphaLISA 
counts vs. the concentration PAI-1 analyte. The 
data was analyzed according to a nonlinear regres-
sion using a 4-parameter logistic equation (sigmoi-
dal dose-response curve with variable slope) and a 
1/Y2 data weighting.
For clinical characteristics (continuous variables) of 
the subjects, a Kolmogorov-Smirnov statistic was 
performed in order to test for normal distribution 
before statistical analyses. Mann-Whitney U tests 
and Wilcoxon tests were performed on unpaired 
and paired data without normal distribution to 
compare values from two groups, and Chi-square 
tests were performed for dichotomous variables. 
To investigate the relationship between salivary 
and plasma PAI-1 concentrations and in the morn-
ing and the in the afternoon samples, nonpara-
metric Spearman product moment correlation co-
efficients were calculated. A P-value < 0.05 is con-
sidered to be statistically significant.
Results
In total 40 healthy subjects were enrolled in the 
study. The details of the subjects are shown in Ta-
ble 1. There were equal number of healthy men 
and women with median age 24 years and median 
body mass index 22.7 kg/m2.
The performance characteristics of the PAI-1 im-
munoassay are summarized in Table 2. Also, the 
PAI-1 assay performed well with an acceptable an-
alyte recovery expectations (75-125%) (30). In addi-
tion, both inter and intra-assay CVs were less than 
10% highlighting the reproducibility of the assay.
Table 1. The biological characteristics of healthy control sub-
jects recruited in this study.
Parameters N = 40
Age (years) 24 (19-36)*
Gender (male:female) 20:20
Ethnicity (Caucasian: Asian) 19:21
Body mass index (kg/m2) 22.7 (18.0-29.2)*
* data are presented as median and range.
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The PAI-1 concentrations in the saliva samples col-
lected in the morning ranged between 13.8-1645.0 
pg/mL with a median value of 394.4 (243.4-833.1) 
pg/mL (Figure 1). The PAI-1 concentration in the 
saliva samples collected in the afternoon ranged 
between 13.8-1331.0 pg/mL with a median value 
of 375.8 (129.1-615.4) pg/mL. There was no signifi-
cant difference between PAI-1 concentrations in 
the saliva samples collected in the morning and in 
the afternoon (P = 0.108) (Figure 2). In fact, there 
was a significant correlation between the morning 
and afternoon samples (P = 0.001, Spearman r = 
0.51, Figure 3).
The PAI-1 concentration in the plasma samples 
ranged between 23.7-582,000 pg/mL with a medi-
an of 59000 (24,000-110,000) pg/mL (Figure 1). 
There was a significant difference between the 
morning and afternoon saliva PAI-1 concentrations 
and plasma PAI-1 concentrations, P < 0.001 (Figure 
2). There was no correlation between plasma PAI-1 
concentrations with either morning or afternoon 
salivary PAI-1 concentrations (P = 0.812 and P = 
0.949, respectively) (Figure 3).
Discussion
AlphaLISA® immunoassays have not been validat-
ed by the manufacturer to be suitable with com-
plex biological matrices such as saliva. We have 
adopted the PAI-1 assay by performing calibration 
curves in saliva and calculating the analyte recov-
ery by spiking saliva samples with PAI-1 analyte. 
The validation of the PAI-1 assay was carried out as 
per FDA guidelines (30). The PAI-1 assay perform-
ance characteristics were acceptable with regard 
to the assay dynamic range, analyte recovery and 
lower limit of detection. Salivary PAI-1 concentra-
tions were not affected by the time of saliva col-
lection. Salivary PAI-1 concentrations were signifi-
cantly lower than plasma concentrations and there 














PAI-1 in saliva 30000 pg/mL = 95.03%300 pg/mL = 94.29% 8.59 (3.9) 7.52 (3.9) 13.8 35.7


























































Figure 2. Comparison of PAI-1 concentrations in the saliva col-
lected in the morning to the saliva samples collected in the af-
ternoon (Spearman correlation coefficient r = 0.51, P=0.001).
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was no correlation between plasma and salivary 
PAI-1 concentrations.
PAI-1 is an important regulator of fibrinolysis at 
sites where vascular injury and thrombus forma-
tion occurs. In this study, we have demonstrated 
that PAI-1 concentrations are detected in saliva 
collected from non-smoking, young healthy sub-
jects. Current assays to quantify PAI-1 concentra-
tions in body fluids are validated to be used with 
plasma samples. The presence of PAI-1 in saliva has 
diagnostic potential and hence it is important to 
develop an immunoassay to reliably quantify this 
analyte. There was a significant correlation be-
tween morning and the afternoon PAI-1 salivary 
concentrations implying that the effect of circadi-
an rhythm is minimal for PAI-1 in saliva. There was 
no correlation between salivary and plasma PAI-1 
concentrations. One possible explanation could be 
that salivary PAI-1 has two sources of origin: in situ 
synthesized in the salivary acinar cells as well as 
the PAI-1 that get transported from the blood en-
dothelium into salivary acinar cells. Diurnal varia-
tion of plasma PAI-1 concentrations has been re-
ported previously (31) which strongly indicates 
salivary PAI-1 has a different origin rather than pas-
sive filtration from blood. A recent study demon-
strated that tissue factor associated with exosomes 
in saliva has the ability to promote blood coagula-
tion (32). Counterbalancing this is the presence of 
PAI-1 which can inhibit fibrinolysis. Further re-
search is required to fully delineate the biological 
role of PAI-1 in unstimulated human whole saliva. 
The stability of PAI-1 in saliva at room temperature 
is not known. Our data demonstrated that at room 
temperature both recombinant PAI-1 and salivary 
PAI-1 remained stable for over 7 hours, and slightly 
degraded post 24-hours (9% loss after 24-hours, 
data not shown).
A study by Virtanen et al. (16) detected plasmino-
gen activators and their inhibitors in cell free hu-
man saliva. They also showed the expression of 
PAI-1 and PAI-2 in normal human submandibular 
and parotid gland tissues (in both acinar and duc-
tal cells) suggesting that these inhibitors are pro-
duced endogenously by salivary glands. However, 
in the study by Virtanen et al. they did not detect 
PAI-1 in human saliva (16). One reason for this dis-
crepancy could arise from the sample of choice (in 
our study we used whole mouth unprocessed sa-
liva and they used cell-free saliva supernatant). We 
have also demonstrated in the past that the meth-
od of saliva collection and processing has an influ-
ence on protein detection (24,25). A second reason 
could be that the method that Virtanen et al., used 
is less sensitive assay than the AlphaLISA® assay 
used in this study. A third reason could be due to 
the differences in the study subjects i.e. we investi-
gated healthy non-smoking subjects as opposed 
to neurological out-patients.
In a previous study (9), we have demonstrated that 
D-dimer, a fibrin degradation product was present 
in unstimulated whole saliva collected from the 
Figure 3. The comparison of PAI-1 concentrations in plasma to (A) saliva samples collected in the morning (Spearman correlation co-
efficient r = 0.01, P= 0.949) and (B) saliva samples collected in the afternoon (Spearman correlation coefficient r = 0.04, P = 0.812).
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same group of healthy subjects. When comparing 
the salivary PAI-1 concentrations and salivary D-
dimer concentrations, we found a strong positive 
correlation between the two biomolecules (P < 
0.001, r = 0.72). In theory, D-dimer concentrations 
and PAI-1 concentrations should be negatively cor-
related since D-dimer is a fibrin degradation prod-
uct and PAI-1 is the inhibitor of fibrin degradation. 
Possible reasons for this positive correlation could 
be due to the fact that these two biomolecules 
have different origins and there is a lag time in the 
secretion of PAI-1 from salivary glands into actual 
saliva. Further studies are needed to shed light 
into the activities of these two biomolecules.
To improve our understanding of CVD, additional 
CVD risk factors such as newer biomarkers from 
distinct biological pathways are need to be inves-
tigated. Blood base markers have been widely 
used for the evaluation of CVD. However, blood is 
not necessarily an ideal diagnostic medium for 
population screening or first line test. The present 
study suggested that salivary PAI-1 assay has the 
potential to become an alternate screening test. 
Although this study using 40 healthy subjects has 
highlighted that salivary PAI-1 concentrations have 
potential, however further larger and long term 
study (including samples from CVD patients) need 
to be utilised to determine its clinical utility.
In summary, we have demonstrated that PAI-1 is 
quantifiable analyte in unstimulated saliva collect-
ed from healthy subjects which implied the poten-
tial clinical utility of a salivary PAI-1 test. The adopt-
ed PAI-1 assay produced acceptable precision, sen-
sitivity and specificity. The concentration of sali-
vary PAI-1 was significantly lower than plasma 
PAI-1 concentrations, and there was no correlation 
between salivary and plasma PAI-1 concentrations. 
These findings suggest that salivary PAI-1 may 
have different origins from plasma PAI-1.
This is a preliminary study to demonstrate that 
PAI-1 is detectable in human whole mouth saliva. 
One of the limitations of the present study is that 
we calculated the LOD of the immunoassay using 
data generated from 9 individual blanks instead of 
20 as described in standard CLSI EP17-A2. Previous 
studies using this technology showed (data not 
shown) with 20 and 9 blanks showed very similar 
outcomes. Therefore, in order to reduce the 
amount of reagent used it was decided 9 blanks 
were sufficient to generate reliable data for calcu-
lating LOD. Another limitation of this study is that 
we did not include CVD patients. To establish a 
clinically reliable reference range guide of salivary 
PAI-1 concentration requires data from a large 
number of healthy controls. The next stage of the 
study should involve a much larger number of 
healthy controls and CVD patients to verify its clin-
ical utility.
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